DNA methylation markers in peripheral blood for psoriatic arthritis.

ABSTRACT

BACKGROUND: The clinical manifestations of psoriatic arthritis (PsA) are highly heterogeneous and no reliable diagnostic biomarkers exist. OBJECTIVE: We explored the role of DNA methylation CpG markers in the diagnosis of PsA. METHODS: DNA methylation array was used to screen for differentially methylated sites (DMSs) in the discovery phase (PsA, n = 25; healthy controls [HCs], n = 19; psoriasis vulgaris [PsV], n = 20). In the validation phase, pyrosequencing was used to identify the DMSs in an expanded cohort (PsA, n = 60; HCs, n = 91; PsV, n = 48; rheumatoid arthritis [RA], n = 60). Logistic regression prediction models were established based on the identified DMSs for the diagnosis of PsA. RESULTS: A total of 17 DMSs differentiating PsA and HCs as well as 11 DMSs differentiating PsA and PsV were screened in the discovery phase. A total of six DMSs (chr14 cg07940072, chr14 38061320, chr9 cg15734589, chr6 cg12800266, chr3 cg12992827, chr6 cg24500972) differentiating PsA and HCs and two DMSs (chr12 cg16459382, chr2 cg16348668) differentiating PsA and PsV were identified using pyrosequencing. Three logistic regression prediction models were established based on the identified DMSs, which distinguished PsA, RA, PsV, and HCs (P < 0.001). The models performed well in differentiating PsA from HCs, RA, and PsV (AUC 0.858, 0.851, and 0.976, respectively). CONCLUSIONS: The models based on methylated CpG sites are useful for distinguishing patients with PsA from HCs and those with RA or PsV and are a highly sensitive and specific diagnostic biomarker for PsA.